Catherine M. Szyman - May 3, 2024 Form 4 Insider Report for Edwards Lifesciences Corp (EW)

Role
CVP, Critical Care
Signature
Linda J. Park, Attorney-in-Fact
Stock symbol
EW
Transactions as of
May 3, 2024
Transactions value $
-$334,174
Form type
4
Date filed
5/6/2024, 07:18 PM
Previous filing
Apr 26, 2024
Next filing
May 9, 2024

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction EW Common Stock Tax liability -$40.7K -479 -1.1% $85.06 43.2K May 3, 2024 Direct
transaction EW Common Stock Options Exercise $0 +5.8K +13.41% $0.00 49K May 4, 2024 Direct F1
transaction EW Common Stock Tax liability -$293K -3.44K -7.02% $85.25 45.6K May 4, 2024 Direct

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction EW Performance Rights Options Exercise $0 -5.8K -100% $0.00* 0 May 4, 2024 Common Stock 5.8K Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 On May 4, 2021, the Reporting Person was granted a target number of shares covered by restricted stock units with performance-based vesting requirements over a three-year performance period. On May 1, 2024, the Compensation and Governance Committee of the Board of Directors determined that 117.11% of the target number of shares would vest as of May 4, 2024, and the actual number of shares vested are reflected on this Form 4.

Remarks:

This Form 4 reflects changes in beneficial ownership only; it does not identify other securities of the Issuer beneficially owned by the Reporting Person. This Form 4 includes quarterly acquisition of shares under the Issuer's Employee Stock Purchase Plan.